Larimar Therapeutics is a biopharmaceutical company that has utilized its proprietary methionine aminopeptidase 2, or MetAP2, biology platform to develop the study of MetAP2 inhibitors in both common and rare metabolic disorders. The LRMR stock yearly return is shown above.
The yearly return on the LRMR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LRMR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|